Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29997540 | 0.89 | MMP13 (0.34) | MMP13ACACBALDH1A1L3MBTL1PRSS1 | |
| SCHEMBL24234513 | 0.88 | MMP13 (0.32) | MMP13ACACB | |
| SCHEMBL24234516 | 0.82 | — | — | |
| SCHEMBL24234509 | 0.77 | PTPN11 (0.41) | ALDH1A1 | |
| SCHEMBL24234510 | 0.76 | RARB (0.38) | MMP13 | |
| SCHEMBL16843258 | 0.74 | P2RY6 (0.31) | MMP13ACACBL3MBTL1P2RY6 | |
| SCHEMBL19534312 | 0.71 | MMP13 (0.34) | MMP13ACACBL3MBTL1PRSS1CTSG | |
| SCHEMBL13832382 | 0.71 | ACACB (0.33) | MMP13ACACBALDH1A1L3MBTL1P2RY6 | |
| SCHEMBL13831123 | 0.71 | ACACB (0.33) | MMP13ACACBALDH1A1L3MBTL1P2RY6 | |
| SCHEMBL16820846 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | HACL2, NAAA, LCT | MMP13 84/4885ACACB 681/4885ALDH1A1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.